Quantum Biopharma Ltd. (QNTM) Institutional Ownership

Ownership Summary

Quantum Biopharma Ltd. (NASDAQ:QNTM) has 23 institutional investors that have filed 13F reports for the period ending December 2025.

• These investors collectively held 3.4% of Quantum Biopharma's outstanding shares in December 2025, up from 1.8% in September 2025.
• Their total shares held in QNTM increased 87.14% quarter over quarter, and separately, investors owning Quantum Biopharma increased 130.0% from a year ago.
• Of these 23 funds, 12 grew their exposure to Quantum Biopharma, 6 cut back, and 5 maintained positions.
• In total, institutional investors held 128.38K shares in Quantum Biopharma as of December 2025, up by 59.78K shares quarter on quarter, and up 58.46K shares year over year.
• As of December 31, 2025, AdvisorShares Investments LLC held the largest stake in Quantum Biopharma with 108.59K shares, accounting for 2.86% of total shares outstanding.
• The most significant purchases of QNTM for the quarter ending December 2025 came from AdvisorShares Investments LLC (58.96K), Platform Technology Partners (41.12K), JANE STREET GROUP, LLC (20.61K), Mariner, LLC (10.06K), UBS Group AG (5.53K).
• The biggest sellers of Quantum Biopharma for the quarter ending December 2025 included Royal Bank Of Canada (36), Rockefeller Capital Management L.P. (30).
• Per Business Quant, the top 10 investors in QNTM for the quarter ending December 2025 include AdvisorShares Investments LLC (108.59K), Platform Technology Partners (41.12K), JANE STREET GROUP, LLC (31.5K), CITADEL ADVISORS LLC (15.86K), Marex Group plc (13.47K), Virtu Financial LLC (12.28K), Mariner, LLC (10.06K), UBS Group AG (7.24K), OSAIC HOLDINGS, INC. (6.38K), Steward Partners Investment Advisory, LLC (4.38K).